The NEJM Trial: Psilocybin vs. Escitalopram for Depression — Full Analysis
About This Video
The 2021 NEJM paper comparing psilocybin to escitalopram for depression is one of the most consequential publications in the history of psychedelic medicine — and one of the most frequently misunderstood. This Imperial College presentation by Robin Carhart-Harris and colleagues provides the authoritative explanation of what the trial found, what it didn't find, and why both matter for clinical practice.
The study design is explained in detail: 59 participants with treatment-resistant depression were randomized to receive either two doses of psilocybin with an escitalopram-matched placebo, or two doses of very low psilocybin with a six-week course of escitalopram. The primary outcome was the QIDS-SR16 depression scale at six weeks.
The headline finding — comparable primary outcome reductions — has been widely misinterpreted as the study 'failing.' Carhart-Harris explains why this is wrong. Comparable primary outcomes means psilocybin performed as well as an approved antidepressant in a six-week window via a two-session intervention. Secondary outcomes strongly favored psilocybin: emotional blunting, anhedonia, and measures of psychological wellbeing all showed substantially greater improvement in the psilocybin arm.
The emotional blunting comparison is particularly clinically important. SSRIs are known to produce emotional blunting — a dulling of the full range of emotional experience — as a side effect that reduces adherence and quality of life. Psilocybin produced no emotional blunting; emotional range and vibrancy increased. For patients who have stopped antidepressants because of emotional blunting, this finding is significant.
Key Takeaways
- Primary outcome: psilocybin and escitalopram produced comparable QIDS-SR16 reductions at six weeks — psilocybin performed as well as an approved antidepressant in a two-session intervention.
- Secondary outcomes favored psilocybin: less emotional blunting, significantly greater improvement in anhedonia and psychological wellbeing measures.
- The emotional blunting comparison is clinically crucial — SSRIs cause emotional blunting; psilocybin did not and produced increased emotional range.
- Key limitations: unblinded design (participants could usually tell their condition), short timeframe, small sample — findings are promising but not definitive.
- The trial's direction of evidence: psilocybin did not underperform escitalopram in any primary measure and outperformed it in several secondary measures.
Dive Deeper
Continue exploring this topic on LearnShrooms: